Anzeige
Erschienen in:
03.07.2023 | Original Article
Urological complications after COVID 19 vaccine according to age, sex and manufacturer
Erschienen in: World Journal of Urology | Ausgabe 8/2023
Einloggen, um Zugang zu erhaltenAbstract
Objectives
To examine the effects of age, sex, and type of COVID-19 vaccine on urological complications after vaccination with COVID-19.
Materials and methods
We used the Vaccine Adverse Event Reporting System (VAERS) data from December 2020 to August 2022 to analyze urological symptoms post-vaccination adverse events (AEs) associated with COVID-19 vaccines authorized for the U.S. population. We collected AEs after 1–2 dose vaccination in VAERS, but not those after an additional booster shot. Age was divided into three groups (< 18 years, 18–64 years, and > 64 years), and compared incidence of AEs after vaccination with either mRNA vaccine (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) or a viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) as reported in VAERS data.
Results
Cumulative incidence rates (CIRs) of LUTS, voiding symptom, storage symptom, infection, and hematuria were 0.057, 0.282, 0.223, 1.245, and 0.214, respectively. By gender, CIRs OF LUTS, storage symptom, and infection were statistically significantly higher in women, whereas CIRs of voiding symptom and hematuria were statistically significantly higher in men. CIRs of AEs per 100,000 in age groups of < 18 years, 18–64 years, and > 64 years were 0.353, 1.403, and 4.067, respectively. All AE types except for voiding symptom displayed the highest CIRs in the Moderna vaccine group.
Conclusions
Based on an updated analysis of available data, the prevalence of urologic complications following administration of COVID-19 vaccines is low. However, specific urologic complications such as gross hematuria are not low in incidence.